Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of:
Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York
This program has been made available online.
Downloadable slides on managing adverse events associated with asparaginase-based therapy in patients with ALL, from Clinical Care Options (CCO)
Downloadable slideset on BTK inhibitors in relapsed/refractory CLL/SLL, from Clinical Care Options (CCO).
Downloadable slideset on BTK inhibitors for the frontline treatment of CLL/SLL from Clinical Care Options (CCO).
Downloadable slideset from Dr. Eytan M. Stein on selecting therapy for AML patients with predictive biomarkers or actionable alterations, from Clinical Care Options (CCO)